On Feb. 16, 2018, a federal judge in Wilmington, DE reversed a 2016 jury verdict requiring Gilead Sciences to pay $2.54 billion for patent infringement to competitor Merck & Co. over Gilead s two best-selling Hepatitis C drugs, Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir). ThOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.